出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2017/11/02 18:20:47」(JST)
Monoclonal antibodies (mAb or moAb) are antibodies that are made by identical immune cells that are all clones of a unique parent cell. Monoclonal antibodies can have monovalent affinity, in that they bind to the same epitope (the part of an antigen that is recognized by the antibody). In contrast, polyclonal antibodies bind to multiple epitopes and are usually made by several different plasma cell (antibody secreting immune cell) lineages. Bispecific monoclonal antibodies can also be engineered, by increasing the therapeutic targets of one single monoclonal antibody to two epitopes.
Given almost any substance, it is possible to produce monoclonal antibodies that specifically bind to that substance; they can then serve to detect or purify that substance. This has become an important tool in biochemistry, molecular biology, and medicine. When used as medications, non-proprietary drug names end in -mab (see "Nomenclature of monoclonal antibodies") and many immunotherapy specialists use the word mab anacronymically.
The idea of "magic bullets" was first proposed by Paul Ehrlich, who, at the beginning of the 20th century, postulated that, if a compound could be made that selectively targeted a disease-causing organism, then a toxin for that organism could be delivered along with the agent of selectivity. He and Élie Metchnikoff received the 1908 Nobel Prize for Physiology or Medicine for this work, which led to an effective syphilis treatment by 1910.
In the 1970s, the B-cell cancer multiple myeloma was known. It was understood that these cancerous B-cells all produce a single type of antibody (a paraprotein). This was used to study the structure of antibodies, but it was not yet possible to produce identical antibodies specific to a given antigen.[1]:324
In 1975, Georges Köhler and César Milstein succeeded in making fusions of myeloma cell lines with B cells to create hybridomas that could produce antibodies, specific to known antigens and that were immortalized.[2] They shared the Nobel Prize in Physiology or Medicine in 1984 for the discovery.[2]
In 1988, Greg Winter and his team pioneered the techniques to humanize monoclonal antibodies,[3] eliminating the reactions that many monoclonal antibodies caused in some patients.
Monoclonal antibodies are typically made by cell culture that involves fusing myeloma cells with mouse spleen cells immunized with the desired antigen. Rabbit B-cells can be used to form a rabbit hybridoma. Polyethylene glycol is used to fuse adjacent plasma membranes,[4] but the success rate is low, so a selective medium in which only fused cells can grow is used. This is possible because myeloma cells have lost the ability to synthesize hypoxanthine-guanine-phosphoribosyl transferase (HGPRT), an enzyme necessary for the salvage synthesis of nucleic acids. The absence of HGPRT is not a problem for these cells unless the de novo purine synthesis pathway is also disrupted. Exposing cells to aminopterin (a folic acid analogue, which inhibits dihydrofolate reductase, DHFR), makes them unable to use the de novo pathway and become fully auxotrophic for nucleic acids, thus requiring supplementation to survive.
The selective culture medium is called HAT medium because it contains hypoxanthine, aminopterin and thymidine. This medium is selective for fused (hybridoma) cells. Unfused myeloma cells cannot grow because they lack HGPRT and thus cannot replicate their DNA. Unfused spleen cells cannot grow indefinitely because of their limited life span. Only fused hybrid cells, referred to as hybridomas, are able to grow indefinitely in the media because the spleen cell partner supplies HGPRT and the myeloma partner has traits that make it immortal (similar to a cancer cell).
This mixture of cells is then diluted and clones are grown from single parent cells on microtitre wells. The antibodies secreted by the different clones are then assayed for their ability to bind to the antigen (with a test such as ELISA or Antigen Microarray Assay) or immuno-dot blot. The most productive and stable clone is then selected for future use.
The hybridomas can be grown indefinitely in a suitable cell culture medium. They can also be injected into mice (in the peritoneal cavity, surrounding the gut). There, they produce tumors secreting an antibody-rich fluid called ascites fluid.
The medium must be enriched during in vitro selection to further favour hybridoma growth. This can be achieved by the use of a layer of feeder fibrocyte cells or supplement medium such as briclone. Culture-media conditioned by macrophages can be used. Production in cell culture is usually preferred as the ascites technique is painful to the animal. Where alternate techniques exist, ascites is considered unethical.[5]
Several monoclonal antibody technologies had been developed recently, such as phage display, single B cell culture,[6] single cell amplification from various B cell populations[7][8][9][10][11] and single plasma cell interrogation technologies. Different from traditional hybridoma technology, the newer technologies use molecular biology techniques to amplify the heavy and light chains of the antibody genes by PCR and produce in either bacterial or mammalian systems with recombinant technology. One of the advantages of the new technologies is applicable to multiple animals, such as rabbit, llama, chicken and other common experimental animals.
After obtaining either a media sample of cultured hybridomas or a sample of ascites fluid, the desired antibodies must be extracted. Cell culture sample contaminants consist primarily of media components such as growth factors, hormones and transferrins. In contrast, the in vivo sample is likely to have host antibodies, proteases, nucleases, nucleic acids and viruses. In both cases, other secretions by the hybridomas such as cytokines may be present. There may also be bacterial contamination and, as a result, endotoxins that are secreted by the bacteria. Depending on the complexity of the media required in cell culture and thus the contaminants, one or the other method (in vivo or in vitro) may be preferable.
The sample is first conditioned, or prepared for purification. Cells, cell debris, lipids and clotted material are first removed, typically by centrifugation followed by filtration with a 0.45 µm filter. These large particles can cause a phenomenon called membrane fouling in later purification steps. In addition, the concentration of product in the sample may not be sufficient, especially in cases where the desired antibody is produced by a low-secreting cell line. The sample is therefore concentrated by ultrafiltration or dialysis.
Most of the charged impurities are usually anions such as nucleic acids and endotoxins. These can be separated by ion exchange chromatography.[12] Either cation exchange chromatography is used at a low enough pH that the desired antibody binds to the column while anions flow through, or anion exchange chromatography is used at a high enough pH that the desired antibody flows through the column while anions bind to it. Various proteins can also be separated along with the anions based on their isoelectric point (pI). In proteins, the isoelectric point (pI) is defined as the pH at which a protein has no net charge. When the pH > pI, a protein has a net negative charge and when the pH < pI, a protein has a net positive charge. For example, albumin has a pI of 4.8, which is significantly lower than that of most monoclonal antibodies, which have a pI of 6.1. Thus, at a pH between 4.8 and 6.1, the average charge of albumin molecules is likely to be more negative, while mAbs molecules are positively charged and hence it is possible to separate them. Transferrin, on the other hand, has a pI of 5.9, so it cannot be easily separated by this method. A difference in pI of at least 1 is necessary for a good separation.
Transferrin can instead be removed by size exclusion chromatography. This method is one of the more reliable chromatography techniques. Since we are dealing with proteins, properties such as charge and affinity are not consistent and vary with pH as molecules are protonated and deprotonated, while size stays relatively constant. Nonetheless, it has drawbacks such as low resolution, low capacity and low elution times.
A much quicker, single-step method of separation is protein A/G affinity chromatography. The antibody selectively binds to protein A/G, so a high level of purity (generally >80%) is obtained. However, this method may be problematic for antibodies that are easily damaged, as harsh conditions are generally used. A low pH can break the bonds to remove the antibody from the column. In addition to possibly affecting the product, low pH can cause protein A/G itself to leak off the column and appear in the eluted sample. Gentle elution buffer systems that employ high salt concentrations are available to avoid exposing sensitive antibodies to low pH. Cost is also an important consideration with this method because immobilized protein A/G is a more expensive resin.
To achieve maximum purity in a single step, affinity purification can be performed, using the antigen to provide specificity for the antibody. In this method, the antigen used to generate the antibody is covalently attached to an agarose support. If the antigen is a peptide, it is commonly synthesized with a terminal cysteine, which allows selective attachment to a carrier protein, such as KLH during development and to support purification. The antibody-containing media is then incubated with the immobilized antigen, either in batch or as the antibody is passed through a column, where it selectively binds and can be retained while impurities are washed away. An elution with a low pH buffer or a more gentle, high salt elution buffer is then used to recover purified antibody from the support.
Product heterogeneity is common in monoclonal antibodies and other recombinant biological products and is typically introduced either upstream during expression or downstream during manufacturing.[citation needed]
These variants are typically aggregates, deamidation products, glycosylation variants, oxidized amino acid side chains, as well as amino and carboxyl terminal amino acid additions.[13] These seemingly minute structural changes can affect preclinical stability and process optimization as well as therapeutic product potency, bioavailability and immunogenicity. The generally accepted purification method of process streams for monoclonal antibodies includes capture of the product target with protein A, elution, acidification to inactivate potential mammalian viruses, followed by ion chromatography, first with anion beads and then with cation beads.[citation needed]
Displacement chromatography has been used to identify and characterize these often unseen variants in quantities that are suitable for subsequent preclinical evaluation regimens such as animal pharmacokinetic studies.[14][15] Knowledge gained during the preclinical development phase is critical for enhanced product quality understanding and provides a basis for risk management and increased regulatory flexibility. The recent Food and Drug Administration’s Quality by Design initiative attempts to provide guidance on development and to facilitate design of products and processes that maximizes efficacy and safety profile while enhancing product manufacturability.[16]
The production of recombinant monoclonal antibodies involves repertoire cloning or phage display/yeast display technologies. Recombinant antibody engineering involves antibody production by the use of viruses or yeast, rather than mice. These techniques rely on rapid cloning of immunoglobulin gene segments to create libraries of antibodies with slightly different amino acid sequences from which antibodies with desired specificities can be selected.[17] The phage antibody libraries are a variant of phage antigen libraries.[18] These techniques can be used to enhance the specificity with which antibodies recognize antigens, their stability in various environmental conditions, their therapeutic efficacy and their detectability in diagnostic applications.[19] Fermentation chambers have been used for large scale antibody production.
While mouse and human antibodies are structurally similar, the differences between them were sufficient to invoke an immune response when murine monoclonal antibodies were injected into humans, resulting in their rapid removal from the blood, as well as systemic inflammatory effects and the production of human anti-mouse antibodies (HAMA).[citation needed]
Recombinant DNA has been explored since the late 1980s to increase residence times. In one approach, mouse DNA encoding the binding portion of a monoclonal antibody was merged with human antibody-producing DNA in living cells. The expression of this "chimeric" or "humanised" DNA through cell culture yielded part-mouse, part-human antibodies.[20]
Ever since the discovery that monoclonal antibodies could be generated, scientists have targeted the creation of "fully" human products to reduce the side effects of humanised or chimeric antibodies. Two successful approaches have been identified: transgenic mice[21] and phage display.
As of November 2016, thirteen of the nineteen "fully" human monoclonal antibody therapeutics on the market were derived from transgenic mice technology.
Adopting organizations who market transgenic technology include:
Phage display can be used to express variable antibody domains on filamentous phage coat proteins (Phage major coat protein).[29][30][31] These phage display antibodies can be used for various research applications.[32][33] ProAb was announced in December 1997[34] and involved high throughput screening of antibody libraries against diseased and non-diseased tissue, whilst Proximol used a free radical enzymatic reaction to label molecules in proximity to a given protein.[35][36]
Monoclonal antibodies have been approved to treat cancer, cardiovascular disease, inflammatory diseases, macular degeneration, transplant rejection, multiple sclerosis and viral infection.
In August 2006 the Pharmaceutical Research and Manufacturers of America reported that U.S. companies had 160 different monoclonal antibodies in clinical trials or awaiting approval by the Food and Drug Administration.[37]
Once monoclonal antibodies for a given substance have been produced, they can be used to detect the presence of this substance. The Western blot test and immuno dot blot tests detect the protein on a membrane. They are also very useful in immunohistochemistry, which detect antigen in fixed tissue sections and immunofluorescence test, which detect the substance in a frozen tissue section or in live cells.
Antibodies can also be used to purify their target compounds from mixtures, using the method of immunoprecipitation.
Therapeutic monoclonal antibodies act through multiple mechanisms, such as blocking of targeted molecule functions, inducing apoptosis in cells which express the target, or by modulating signalling pathways.[38][39]
One possible treatment for cancer involves monoclonal antibodies that bind only to cancer cell-specific antigens and induce an immune response against the target cancer cell. Such mAbs can be modified for delivery of a toxin, radioisotope, cytokine or other active conjugate or to design bispecific antibodies that can bind with their Fab regions both to target antigen and to a conjugate or effector cell. Every intact antibody can bind to cell receptors or other proteins with its Fc region.
MAbs approved by the FDA (for cancer) as of 2005 include:[41]
Monoclonal antibodies used for autoimmune diseases include infliximab and adalimumab, which are effective in rheumatoid arthritis, Crohn's disease, ulcerative Colitis and ankylosing spondylitis by their ability to bind to and inhibit TNF-α.[42] Basiliximab and daclizumab inhibit IL-2 on activated T cells and thereby help prevent acute rejection of kidney transplants.[42] Omalizumab inhibits human immunoglobulin E (IgE) and is useful in moderate-to-severe allergic asthma.
Monoclonal antibodies for research applications can be found directly from antibody suppliers, or through use of a specialist search engine like CiteAb. Below are examples of clinically important monoclonal antibodies.
| Main category | Type | Application | Mechanism/Target | Mode |
|---|---|---|---|---|
| Anti- inflammatory |
infliximab[42] |
|
inhibits TNF-α | chimeric |
| adalimumab |
|
inhibits TNF-α | human | |
| basiliximab[42] |
|
inhibits IL-2 on activated T cells | chimeric | |
| daclizumab[42] |
|
inhibits IL-2 on activated T cells | humanized | |
| omalizumab |
|
inhibits human immunoglobulin E (IgE) | humanized | |
| gemtuzumab[42] |
|
targets myeloid cell surface antigen CD33 on leukemia cells | humanized | |
| Anti-cancer | alemtuzumab[42] |
|
targets an antigen CD52 on T- and B-lymphocytes | humanized |
| rituximab[42] |
|
targets phosphoprotein CD20 on B lymphocytes | chimeric | |
| trastuzumab |
|
targets the HER2/neu (erbB2) receptor | humanized | |
| nimotuzumab |
|
EGFR inhibitor | humanized | |
| cetuximab |
|
EGFR inhibitor | chimeric | |
| bevacizumab & ranibizumab |
|
inhibits VEGF | humanized | |
| Anti-cancer and anti-viral | bavituximab[43] |
|
immunotherapy, targets phosphatidylserine[43] | chimeric |
| Other | palivizumab[42] |
|
inhibits an RSV fusion (F) protein | humanized |
| abciximab[42] |
|
inhibits the receptor GpIIb/IIIa on platelets | chimeric |
| Library resources about Monoclonal antibody |
|
Immunology: lymphocytic adaptive immune system and complement
|
|||||||||
|---|---|---|---|---|---|---|---|---|---|
| Lymphoid |
|
||||||||
| Lymphocytes |
|
||||||||
| Substances |
|
||||||||
|
Monoclonal antibodies ("-mab")
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Engineered monoclonal antibodies and antibody mimetics
|
||
|---|---|---|
| Whole antibody |
|
|
| Fab fragment |
|
|
| Variable fragment |
|
|
| Smaller units |
|
|
| Intracellular |
|
|
| Antibody mimetics |
|
|
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
| リンク元 | 「モノクローナル抗体」「単クローン抗体」 |
| 拡張検索 | 「humanized monoclonal antibody」「specific monoclonal antibody」「OKT3 monoclonal antibody」 |
| 関連記事 | 「monoclonal」 |
| マーカー名 | 陽性となる正常組織・腫瘍 |
| サイトケラチン | 上皮系細胞 |
| CAM 5.2（CK7 ＋ CK8） | 汗腺、中皮腫（肺腺癌で陰性 |
| サイトケラチン20 | Merkel細胞 |
| EMA（epithelial membrane antigen, episialin） | 上皮、上皮性腫瘍（染色性やや悪い） |
| vimentin | 間葉系細胞 |
| desmin | 横紋筋、平滑筋 |
| alpha-smooth muscle actin | 横紋筋、平滑筋 |
| NSE（neuron specific enolase） | Schwann細胞、メラノサイト、軟骨細胞 |
| S-100 蛋白 | 神経細胞、傍神経節細胞、神経筋接合部 |
| HMB45, MELAN A | 悪性黒色腫 |
| CEA（carcinoembryonic antigen, CD66e） | 汗腺、消化管間質腫瘍（GIST） |
| Ki-67（MIB-1） | proliferatingmarker |
| factor Ⅷ | 血管内皮細胞 |
| factor ⅩⅢ | 内皮細胞、真皮樹状細胞 |
| GCDFP（gross cystic disease fluid protein）-15 | 汗腺系 |
| CD1a | Langerhans細胞 |
| CD3 | T細胞 |
| CD4 | 活性型T細胞 |
| CD8 | 細胞傷害性T細胞 |
| CD20（L26） | B細胞 |
| CD30（Ki-1） | Hodgkin病、未分化大細胞リンパ腫（ALCL） |
| CD31 | 血管内皮、線維性腫瘍、白血病 |
| CD34 | 血管内皮、血管腫、隆起性皮膚線維肉腫 |
| CD56 | NK細胞 |
| CD68 | マクロファージ、ミエロイド細胞 |
| CD79a | B細胞 |
| BCL6 | MALTリンパ腫 |
| cyclin D1 | マントル細胞リンパ腫 |